895 related articles for article (PubMed ID: 26017313)
21. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
22. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase.
Fong JE; Le Nihouannen D; Komarova SV
J Biol Chem; 2010 Oct; 285(41):31427-34. PubMed ID: 20679341
[TBL] [Abstract][Full Text] [Related]
23. Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis.
Osawa T; Ohga N; Akiyama K; Hida Y; Kitayama K; Kawamoto T; Yamamoto K; Maishi N; Kondoh M; Onodera Y; Fujie M; Shinohara N; Nonomura K; Shindoh M; Hida K
Br J Cancer; 2013 Oct; 109(8):2237-47. PubMed ID: 24045659
[TBL] [Abstract][Full Text] [Related]
24. Lysyl oxidase (LOX) and hypoxia-induced metastases.
Sion AM; Figg WD
Cancer Biol Ther; 2006 Aug; 5(8):909-11. PubMed ID: 16969095
[TBL] [Abstract][Full Text] [Related]
25. Regulation of Breast Cancer-Induced Osteoclastogenesis by MacroH2A1.2 Involving EZH2-Mediated H3K27me3.
Kim J; Shin Y; Lee S; Kim M; Punj V; Lu JF; Shin H; Kim K; Ulmer TS; Koh J; Jeong D; An W
Cell Rep; 2018 Jul; 24(1):224-237. PubMed ID: 29972783
[TBL] [Abstract][Full Text] [Related]
26. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
[TBL] [Abstract][Full Text] [Related]
27. Cancer: Opening LOX to metastasis.
Erez N
Nature; 2015 Jun; 522(7554):41-2. PubMed ID: 26017311
[No Abstract] [Full Text] [Related]
28. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
[TBL] [Abstract][Full Text] [Related]
29. Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.
Brown HK; Ottewell PD; Evans CA; Holen I
Clin Exp Metastasis; 2012 Dec; 29(8):927-38. PubMed ID: 22562502
[TBL] [Abstract][Full Text] [Related]
30. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy.
El-Haibi CP; Bell GW; Zhang J; Collmann AY; Wood D; Scherber CM; Csizmadia E; Mariani O; Zhu C; Campagne A; Toner M; Bhatia SN; Irimia D; Vincent-Salomon A; Karnoub AE
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17460-5. PubMed ID: 23033492
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
[TBL] [Abstract][Full Text] [Related]
32. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
[TBL] [Abstract][Full Text] [Related]
33. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis.
Jin L; Zhang Y; Li H; Yao L; Fu D; Yao X; Xu LX; Hu X; Hu G
Cell Res; 2012 Sep; 22(9):1356-73. PubMed ID: 22688893
[TBL] [Abstract][Full Text] [Related]
34. In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells.
Rucci N; Ricevuto E; Ficorella C; Longo M; Perez M; Di Giacinto C; Funari A; Teti A; Migliaccio S
Bone; 2004 Apr; 34(4):697-709. PubMed ID: 15050901
[TBL] [Abstract][Full Text] [Related]
35. miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes.
Croset M; Pantano F; Kan CWS; Bonnelye E; Descotes F; Alix-Panabières C; Lecellier CH; Bachelier R; Allioli N; Hong SS; Bartkowiak K; Pantel K; Clézardin P
Cancer Res; 2018 Sep; 78(18):5259-5273. PubMed ID: 30042152
[TBL] [Abstract][Full Text] [Related]
36. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
37. The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer.
Wang N; Reeves KJ; Brown HK; Fowles AC; Docherty FE; Ottewell PD; Croucher PI; Holen I; Eaton CL
J Exp Clin Cancer Res; 2015 Oct; 34():124. PubMed ID: 26480944
[TBL] [Abstract][Full Text] [Related]
38. Cancer: LOX does some prepping.
Villanueva MT
Nat Rev Drug Discov; 2015 Jul; 14(7):458-9. PubMed ID: 26129796
[No Abstract] [Full Text] [Related]
39. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis.
Das S; Samant RS; Shevde LA
J Biol Chem; 2011 Mar; 286(11):9612-22. PubMed ID: 21169638
[TBL] [Abstract][Full Text] [Related]
40. Metastasis: LOX does some prepping.
Villanueva MT
Nat Rev Cancer; 2015 Jul; 15(7):384. PubMed ID: 26084391
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
